Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ERNA Eterna Therapeutics Inc.

Not Yet Opened 09-18 16:00:00 EDT

3.83

+0.07

+1.86%

盘后3.83

+0.000.00%

19:59 EDT

High3.89	Low3.79	Vol8.27K
Open3.79	D1 Closing3.76	Amplitude2.53%
Mkt Cap6.25M	Tradable Cap4.61M	Total Shares1.63M
T/O31.80K	T/O Rate0.69%	Tradable Shares1.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ERNA","market":"US","secType":"STK","nameCN":"Eterna Therapeutics Inc.","latestPrice":3.83,"timestamp":1789761600000,"preClose":3.76,"halted":0,"volume":8274,"hourTrading":{"tag":"盘后","latestPrice":3.83,"preClose":3.83,"latestTime":"19:59 EDT","volume":109,"amount":436.48,"timestamp":1789775954949,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01861702127659582,"floatShares":1202700,"shares":1632400,"eps":-18.605883,"marketStatus":"Not Yet Opened","change":0.07,"latestTime":"09-18 16:00:00 EDT","open":3.79,"high":3.885,"low":3.79,"amount":31799.3293338,"amplitude":0.025266,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-18.605883,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":0,"adr":0,"listingDate":465451200000,"exchange":"NASDAQ","adjPreClose":3.76,"preHourTrading":{"tag":"盘前","latestPrice":3.7603,"preClose":3.76,"latestTime":"08:37 EDT","volume":148,"amount":558.8908016,"timestamp":1789735078442,"change":0.0003,"changeRate":0.00008,"amplitude":0.037234},"postHourTrading":{"tag":"盘后","latestPrice":3.83,"preClose":3.83,"latestTime":"19:59 EDT","volume":109,"amount":436.48,"timestamp":1789775954949,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.06465736133375742},"requestUrl":"/m/hq/s/ERNA/tweets","defaultTab":"tweets","newsList":[{"id":"2668497935","title":"Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2668497935","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668497935?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:51","pubTimestamp":1789591885,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics appoints Robert J. Spiegel to board of directorsErnexa Therapeutics appointed Robert J. Spiegel, M.D., to its board, effective Sept. 14, 2026.Spiegel will serve until a successor i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL6B98FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667647881","title":"Ernexa Therapeutics - Intends to Broaden Oncology Program and Advance Next-Generation Imsc Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2667647881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667647881?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667642078","title":"Ernexa Therapeutics - to Concentrate Near-Term Resources on Erna-101 and Broaden Oncology Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667642078?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667642073","title":"Ernexa Therapeutics Reports Positive Disease Modifying Erna-201 Preclinical Data, Reinforcing Imsc Platform as Company Accelerates Oncology Strategy and Erna-101 Toward First-in-Human Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667642073?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667642029","title":"Ernexa Therapeutics - to Advance Erna-101 Toward Ind Submission for Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667642029?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667642027","title":"Ernexa Therapeutics - Clinical Data from Erna-101 Proc Study Expected in Q4 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667642027?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667464202","title":"Ernexa Therapeutics - Pauses Additional Preclinical Development Expenditures on Erna-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2667464202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667464202?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667640583","title":"Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2667640583","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667640583?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":"ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC pla","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/15/3362094/0/en/ernexa-therapeutics-reports-positive-disease-modifying-erna-201-preclinical-data-reinforcing-imsc-platform-as-company-accelerates-oncology-strategy-and-erna-101-toward-first-in-hum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CIA","BK4162","PROC","ERNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667669303","title":"Ernexa Therapeutics CEO Sanjeev Luther Presents at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2667669303","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667669303?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:05","pubTimestamp":1789391150,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics CEO Sanjeev Luther presents at H.C. Wainwright Global Investment ConferenceErnexa will present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 16, 2026.CEO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL1wbns3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","LU2095319765.USD","IE00B64PRP62.GBP","BCDF","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014021.USD","BK4588","BK4139","SG9999014013.SGD","LU0314104364.USD","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","NDAQ","BK4112","LU2210150020.SGD","ERNA","IE00BKPKM429.USD","BK4585","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662090031","title":"Ernexa Therapeutics Director David Polinsky Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2662090031","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662090031?lang=en_us&edition=fundamental","pubTime":"2026-08-28 07:53","pubTimestamp":1787874802,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics director David Polinsky files initial beneficial ownership statementDirector David Polinsky reported 8,000 Ernexa Therapeutics common shares held indirectly through Polo3K, LLC in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL12SfH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662202700","title":"Ernexa Therapeutics Posts On-Demand Video Webcast of Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2662202700","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662202700?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:02","pubTimestamp":1787835772,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics posts on-demand video webcast of investor presentationErnexa Therapeutics published an on-demand video webcast presentation from a Virtual Investor “Why Now” conference. LinkPresen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDLcbsMZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4139","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","BK4588","IE00B64PRP62.GBP","BCDF","SG9999014013.SGD","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU0314104364.USD","IE00BQXX3C00.GBP","BK4112","ERNA","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00BQXX3F31.USD","SG9999014039.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993909","title":"Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993909","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993909?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:01","pubTimestamp":1786366860,"startTime":"0","endTime":"0","summary":"Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governanceAppointment further streng","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","IND","XBI","BK4539","BK4581","BBP","BK4205","BK4007","BK4139","BK4588","RFL","SYNB","ERNA","LENZ","BK4233","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657621266","title":"Ernexa Therapeutics Inc Expected to Post a Loss of $3.84 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657621266","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657621266?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:51","pubTimestamp":1786143065,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics Inc <ERNA.OQ> expected to post a loss of $3.84 a share - Earnings PreviewErnexa Therapeutics IncERNA.OQERNA.Ois expected to  report resultson November 5  for the period ending September 30 2026LSEG's mean analyst estimate for Ernexa Therapeutics Inc is for a loss of $3.84 per share.The one available analyst rating on the shares is \"buy\".The mean earnings estimate of analysts had fallen by about 56.4% in the last three months. Wall Street's median 12-month price target for Ernexa Therapeutics Inc is $30.00, about 612.6% above its last closing price of $4.21This summary was machine generated August 7 at 22:51 GMT.  All figures in US dollars unless otherwise stated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669117","title":"Ernexa Q2 Net Loss Widens to $4.01 Million; Reports no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669117","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669117?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:21","pubTimestamp":1786054899,"startTime":"0","endTime":"0","summary":"Ernexa Q2 net loss widens to $4.01 million; reports no revenueErnexa posted a net loss of USD 4.01 million for the quarter ended June 30, 2026, widening from USD 3.14 million a year earlier.Operating ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6tZypZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653087260","title":"Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2653087260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653087260?lang=en_us&edition=fundamental","pubTime":"2026-07-24 21:20","pubTimestamp":1784899228,"startTime":"0","endTime":"0","summary":"Ernexa CEO says ERNA-101 aims to boost combination immunotherapy in solid tumorsErnexa management outlined a strategy to position ERNA-101 as a combination partner for immunotherapies by targeting the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDLKtbt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","NDAQ","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4112","BCDF","LU0314104364.USD","LU2095319765.USD","BK4139","SG9999014013.SGD","BK4585","ERNA","BK4588","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653801210","title":"Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2653801210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653801210?lang=en_us&edition=fundamental","pubTime":"2026-07-24 21:20","pubTimestamp":1784899200,"startTime":"0","endTime":"0","summary":"CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically \"Cold\" Tumors Into Targets for the Immune System  Video Show","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/24/3332875/0/en/Ernexa-Therapeutics-CEO-Corner-Emphasizes-How-ERNA-101-Could-Help-Unlock-the-Next-Generation-of-Combination-Cancer-Therapies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651266466","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2651266466","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651266466?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:39","pubTimestamp":1784122769,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:39 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nAQN2M857Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651646874","title":"Ernexa Therapeutics announces new ERNA-101 preclinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651646874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651646874?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:15","pubTimestamp":1784117721,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","SYNB","IBBQ","IBB","GNOM","FBT","CNCR","BK4588","ERNA","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450470","title":"Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450470","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651450470?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:50","pubTimestamp":1784116218,"startTime":"0","endTime":"0","summary":"Ernexa says ERNA-101 plus anti-PD-1 clears tumors in ovarian cancer preclinical studyErnexa reported independent CRO validation of ERNA-101 combined with anti-PD-1 in an ovarian cancer model.Combinati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL7twrfS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","ERNA","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4139","SG9999014021.USD","SG9999014005.SGD","NDAQ","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","BCDF","SG9999014013.SGD","LU2095319765.USD","BK4585","SG9999014039.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651504214","title":"Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651504214","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651504214?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:50","pubTimestamp":1784116211,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H18I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ernexatx.com","stockEarnings":[{"period":"1week","weight":-0.0804},{"period":"1month","weight":-0.1354},{"period":"3month","weight":-0.3823},{"period":"6month","weight":-0.4234},{"period":"1year","weight":-0.8794},{"period":"ytd","weight":-0.8723}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.558824,"avgChangeRate":0.130666},{"month":2,"riseRate":0.382353,"avgChangeRate":-0.039626},{"month":3,"riseRate":0.558824,"avgChangeRate":0.018953},{"month":4,"riseRate":0.352941,"avgChangeRate":0.335049},{"month":5,"riseRate":0.411765,"avgChangeRate":0.015195},{"month":6,"riseRate":0.5,"avgChangeRate":0.005635},{"month":7,"riseRate":0.257143,"avgChangeRate":-0.04689},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.016811},{"month":9,"riseRate":0.314286,"avgChangeRate":-0.031673},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.041231},{"month":11,"riseRate":0.5,"avgChangeRate":0.055021},{"month":12,"riseRate":0.323529,"avgChangeRate":-0.050712}],"exchange":"NASDAQ","name":"Eterna Therapeutics Inc.","nameEN":"Eterna Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eterna Therapeutics Inc.,ERNA,Eterna Therapeutics Inc.股票,Eterna Therapeutics Inc.股票老虎,Eterna Therapeutics Inc.股票老虎国际,Eterna Therapeutics Inc.行情,Eterna Therapeutics Inc.股票行情,Eterna Therapeutics Inc.股价,Eterna Therapeutics Inc.股市,Eterna Therapeutics Inc.股票价格,Eterna Therapeutics Inc.股票交易,Eterna Therapeutics Inc.股票购买,Eterna Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction